Who is sponsoring NCT01787487?

NCT01787487 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT01787487?

Interventions in NCT01787487: Azacitidine, Laboratory Biomarker Analysis, Ruxolitinib Phosphate.

Is NCT01787487 still recruiting?

NCT01787487 is currently completed. Last updated 31 March 2026.

Last reviewed 2026-03-31 · How we verify

NCT01787487

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Completed Phase 2 Last updated 31 March 2026

What this trial tests

Phase 2 trial testing Azacitidine in Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable in 121 participants. Completed in 20 January 2026.

Timeline

13 March 2013

Primary endpoint
20 January 2026

20 January 2026

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	121
Start date	13 March 2013
Primary completion	20 January 2026
Estimated completion	20 January 2026
Sites	1 location across United States

Drugs / interventions tested

Azacitidine (azacitidine) — full drug profile →
Laboratory Biomarker Analysis — full drug profile →
Ruxolitinib Phosphate — full drug profile →

Conditions studied

Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable — all drugs for Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable →
Myelofibrosis Transformation in Essential Thrombocythemia — all drugs for Myelofibrosis Transformation in Essential Thrombocythemia →
Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase — all drugs for Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase →
Primary Myelofibrosis — all drugs for Primary Myelofibrosis →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable or Myelofibrosis Transformation in Essential Thrombocythemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial studies how well ruxolitinib phosphate and azacytidine work in treating patients with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacytidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ruxolitinib phosphate and azacytidine may be an effective treatment for myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.
Cheng Y, He C, Wang M, Ma X, et al · · 2019 · cited 760× · PMID 31871779 · DOI 10.1038/s41392-019-0095-0
Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends.
Nepali K, Liou JP. · · 2021 · cited 122× · PMID 33840388 · DOI 10.1186/s12929-021-00721-x
JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition.
Luo Y, Alexander M, Gadina M, O'Shea JJ, et al · · 2021 · cited 92× · PMID 34625141 · DOI 10.1016/j.jaci.2021.08.004
Molecular pathogenesis of the myeloproliferative neoplasms.
Greenfield G, McMullin MF, Mills K. · · 2021 · cited 83× · PMID 34193229 · DOI 10.1186/s13045-021-01116-z
JAK2 inhibitors for myeloproliferative neoplasms: what is next?
Bose P, Verstovsek S. · · 2017 · cited 78× · PMID 28500170 · DOI 10.1182/blood-2017-04-742288
Management of myelofibrosis after ruxolitinib failure.
Harrison CN, Schaap N, Mesa RA. · · 2020 · cited 70× · PMID 32198525 · DOI 10.1007/s00277-020-04002-9
Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.
Badar T, Kantarjian HM, Ravandi F, Jabbour E, et al · · 2015 · cited 67× · PMID 26183878 · DOI 10.1016/j.leukres.2015.06.001
A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.
Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, et al · · 2018 · cited 61× · PMID 30185431 · DOI 10.1182/blood-2018-04-846626

Verify or expand the search:

Other trials of Azacitidine

Trials testing the same drug.

NCT07508982 — Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML · Phase 1, PHASE2 · not yet recruiting
NCT05554419 — Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Tr · Phase 2 · not yet recruiting
NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting
NCT07469046 — VAH vs VA in Newly Diagnosed Elderly AML · Phase 3 · not yet recruiting
NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting

Other recruiting trials for Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable

Currently open trials in the same condition.

NCT03862157 — Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia · Phase 1, PHASE2 · active not recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01787487 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 31 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01787487.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing